Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Investor Update
Get the latest updates from Investor Update directly as they happen.
Follow now 335 followers
Latest posts
Last updated 1 day ago
Roche unveils a new class of next-generation sequencing with its novel sequencing by expansion technology
1 day ago
Roche's innovative sequencing by expansion (SBX) technology represents a leap forward in...
Reminder: Invitation to Roche’s Virtual Event on the SBX (sequencing by expansion) technology
5 days ago
We are pleased to invite investors and analysts to participate in our...
Invitation to Roche’s Virtual Event on the SBX (sequencing by expansion) technology
12 days ago
We are pleased to invite investors and analysts to participate in our...
New England Journal of Medicine publishes new data for Roche’s Gazyva/Gazyvaro which shows superiority over standard therapy in people with active lupus nephritis
15 days ago
Nearly half of patients on Gazyva/Gazyvaro plus standard therapy achieved a complete...
FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness
18 days ago
Susvimo is the first and only continuous delivery treatment that offers an...
Invitation to Roche’s Virtual Immunology/WCN Investor Event
19 days ago
We are pleased to invite investors and analysts to participate in our...
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth
23 days ago
Basel, 30 January 2025 Group sales grew by 7%1 at constant exchange...
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth
23 days ago
Group sales grew by 7%1 at constant exchange rates (CER; 3% in...
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth
23 days ago
Basel, 30 January 2025 Group sales grew by 7%1 at constant exchange...
Roche’s Itovebi demonstrated statistically significant and clinically meaningful overall survival benefit in a certain type of HR-positive advanced breast cancer
25 days ago
Updated overall survival (OS) results - a key secondary endpoint - reinforce...
Roche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular dystrophy (DMD)
26 days ago
Across three key functional outcomes, North Star Ambulatory Assessment (NSAA), Time to...
Reminder: Invitation to Roche’s Full Year Results 2024 Presentation
30 days ago
Roche will publish its Full Year Results of 2024 prior to the...